BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025

  July 16, 2025

   · 

  1 min read
• Press Releases

  Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy

  July 16, 2025

   · 

  15 min read
• Press Releases

  Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

  July 16, 2025

   · 

  7 min read
• Press Releases

  Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

  July 16, 2025

   · 

  10 min read
• Press Releases

  Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA

  July 16, 2025

   · 

  6 min read
• Press Releases

  SELLAS Meets All Primary Endpoints in Phase 2 Trial of SLS009 in r/r AML and Receives FDA Guidance to Advance into First-Line Therapy Study

  July 16, 2025

   · 

  10 min read
• Press Releases

  Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

  July 16, 2025

   · 

  6 min read
• Press Releases

  Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

  July 16, 2025

   · 

  9 min read
• Press Releases

  AAVantgarde Receives FDA Clearance to Progress Stargardt Disease Asset, AAVB-039, into CELESTE, a Phase 1/2 Clinical Trial

  July 16, 2025

   · 

  4 min read
• Press Releases

  Aurora Spine Announces Participation in 7th Annual American Society of Pain & Neuroscience Conference

  July 16, 2025

   · 

  2 min read